Frequently Asked Questions

Why is Post-Translational Modification (PTM) analysis of AAV capsids a focus for CMC?

PTM analysis is a core component of product characterization. Modifications to capsid viral proteins (VPs) can influence vector stability, infectivity, and immunogenicity (PMID: 30343890). A detailed PTM profile provides a molecular signature of the product, which is expected by regulatory bodies to ensure product consistency between lots.

What specific PTMs can mass spectrometry identify on AAV capsid proteins?

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify and localize a range of modifications on VP1, VP2, and VP3. Common PTMs include oxidation, deamidation, phosphorylation, acetylation, and glycosylation. This method provides peptide-level resolution of modification sites.

How does this analytical data support regulatory submissions?

This characterization data forms a component of the Chemistry, Manufacturing, and Controls (CMC) section of an Investigational New Drug (IND) application. It demonstrates a deep understanding of the product’s quality attributes and supports the rationale for the manufacturing process controls.

The molecular integrity of AAV capsids is a primary determinant of efficacy for advanced therapeutics. For these complex biologics, minor variations in protein structure can have significant downstream consequences. Applying proven intelligence in mass spectrometry provides the analytical clarity needed to accelerate next-generation therapies by defining these subtle but meaningful attributes.

Post-translational modifications on capsid viral proteins can arise during the manufacturing process. These modifications are not directly encoded by the vector genome and can affect the product’s biological function. A comprehensive characterization of the PTM profile is a requirement for understanding product consistency and stability.

Our approach utilizes high-resolution mass spectrometry to build a detailed map of capsid protein modifications. This analytical technique provides definitive identification and site-specific localization of various PTMs.

Key characterization targets include:

• Oxidation: Methionine and tryptophan residues are susceptible to oxidation, which can alter protein conformation.
• Deamidation: Asparagine and glutamine residues can undergo deamidation, potentially impacting capsid assembly and receptor binding.
• Phosphorylation: The phosphorylation status of serine, threonine, and tyrosine residues can influence cellular signaling and vector trafficking.
• Acetylation: N-terminal and lysine acetylation can affect protein stability and interactions.

This level of product understanding is necessary when interpreting complex in vivo results. For instance, the selection of an optimal AAV serotype is a critical factor in achieving desired tissue tropism and transduction efficiency, with ongoing research expanding the toolkit of available vectors (PMID: 15975006). A fully characterized vector, with a well-defined PTM profile, is a prerequisite for accurately interpreting such outcomes and minimizing clinical risk. This data ensures that observed biological effects are attributed to the therapeutic design, not to uncharacterized product variability.

The resulting PTM profile serves as a product-specific fingerprint, enabling robust lot-to-lot comparability and supporting the development of a scalable AAV manufacturing process under GLP conditions.